Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Synthesis and characterization of a PDMS-PMOXA based polymersomes sensitive to MMP-9 for application in breast cancer.

Porta F, Ehrsam D, Lengerke C, Meyer Zu Schwabedissen HE.

Mol Pharm. 2018 Oct 1. doi: 10.1021/acs.molpharmaceut.8b00521. [Epub ahead of print]

PMID:
30274515
2.

Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.

Leuppi-Taegtmeyer A, Duthaler U, Hammann F, Schmid Y, Dickenmann M, Amico P, Jehle AW, Kalbermatter S, Lenherr C, Meyer Zu Schwabedissen HE, Haschke M, Liechti ME, Krähenbühl S.

Nephrol Dial Transplant. 2018 Sep 5. doi: 10.1093/ndt/gfy285. [Epub ahead of print]

PMID:
30189012
3.

The scaffold protein PDZK1 modulates expression and function of the organic anion transporting polypeptide 2B1.

Ferreira C, Hagen P, Stern M, Hussner J, Zimmermann U, Grube M, Meyer Zu Schwabedissen HE.

Eur J Pharm Sci. 2018 Jul 30;120:181-190. doi: 10.1016/j.ejps.2018.05.006. Epub 2018 May 9.

PMID:
29752999
4.

Thyroid Hormones Are Transport Substrates and Transcriptional Regulators of Organic Anion Transporting Polypeptide 2B1.

Meyer Zu Schwabedissen HE, Ferreira C, Schaefer AM, Oufir M, Seibert I, Hamburger M, Tirona RG.

Mol Pharmacol. 2018 Jul;94(1):700-712. doi: 10.1124/mol.117.111161. Epub 2018 May 7.

PMID:
29735582
5.

LST-3TM12 is a member of the OATP1B family and a functional transporter.

Malagnino V, Hussner J, Seibert I, Stolzenburg A, Sager CP, Meyer Zu Schwabedissen HE.

Biochem Pharmacol. 2018 Feb;148:75-87. doi: 10.1016/j.bcp.2017.12.012. Epub 2017 Dec 15.

PMID:
29248594
6.

No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA.

Vizeli P, Meyer Zu Schwabedissen HE, Liechti ME.

Eur J Clin Pharmacol. 2018 Mar;74(3):275-283. doi: 10.1007/s00228-017-2392-2. Epub 2017 Dec 2.

7.

PDZ domain containing protein 1 (PDZK1), a modulator of membrane proteins, is regulated by the nuclear receptor THRβ.

Ferreira C, Prestin K, Hussner J, Zimmermann U, Meyer Zu Schwabedissen HE.

Mol Cell Endocrinol. 2018 Feb 5;461:215-225. doi: 10.1016/j.mce.2017.09.017. Epub 2017 Sep 18.

PMID:
28928085
8.

Functional assessment of genetic variants located in the promoter of SHP1 (NR0B2).

Prestin K, Olbert M, Hussner J, Völzke H, Meyer Zu Schwabedissen HE.

Pharmacogenet Genomics. 2017 Nov;27(11):410-415. doi: 10.1097/FPC.0000000000000310.

PMID:
28873070
9.

Doxorubicin enhances oxysterol levels resulting in a LXR-mediated upregulation of cardiac cholesterol transporters.

Monzel JV, Budde T, Meyer Zu Schwabedissen HE, Schwebe M, Bien-Möller S, Lütjohann D, Kroemer HK, Jedlitschky G, Grube M.

Biochem Pharmacol. 2017 Nov 15;144:108-119. doi: 10.1016/j.bcp.2017.08.008. Epub 2017 Aug 12.

PMID:
28807695
10.

Regulation of PDZ domain-containing 1 (PDZK1) expression by hepatocyte nuclear factor-1α (HNF1α) in human kidney.

Prestin K, Hussner J, Ferreira C, Seibert I, Breitung V, Zimmermann U, Meyer Zu Schwabedissen HE.

Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F973-F983. doi: 10.1152/ajprenal.00650.2016. Epub 2017 Jul 19.

11.

Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas.

Kim M, Deacon P, Tirona RG, Kim RB, Pin CL, Meyer Zu Schwabedissen HE, Wang R, Schwarz UI.

Histochem Cell Biol. 2017 Oct;148(4):345-357. doi: 10.1007/s00418-017-1580-6. Epub 2017 May 10.

PMID:
28493059
12.

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects.

Vizeli P, Schmid Y, Prestin K, Meyer Zu Schwabedissen HE, Liechti ME.

Eur Neuropsychopharmacol. 2017 Mar;27(3):232-238. doi: 10.1016/j.euroneuro.2017.01.008. Epub 2017 Jan 20.

PMID:
28117133
13.

Modulation of expression of the nuclear receptor NR0B2 (small heterodimer partner 1) and its impact on proliferation of renal carcinoma cells.

Prestin K, Olbert M, Hussner J, Isenegger TL, Gliesche DG, Böttcher K, Zimmermann U, Meyer Zu Schwabedissen HE.

Onco Targets Ther. 2016 Aug 8;9:4867-78. doi: 10.2147/OTT.S106926. eCollection 2016.

14.

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals.

Schmid Y, Vizeli P, Hysek CM, Prestin K, Meyer Zu Schwabedissen HE, Liechti ME.

Pharmacogenet Genomics. 2016 Aug;26(8):397-401. doi: 10.1097/FPC.0000000000000231.

15.

Secreted Matrix Metalloproteinase-9 of Proliferating Smooth Muscle Cells as a Trigger for Drug Release from Stent Surface Polymers in Coronary Arteries.

Gliesche DG, Hussner J, Witzigmann D, Porta F, Glatter T, Schmidt A, Huwyler J, Meyer Zu Schwabedissen HE.

Mol Pharm. 2016 Jul 5;13(7):2290-300. doi: 10.1021/acs.molpharmaceut.6b00033. Epub 2016 Jun 9.

PMID:
27241028
16.

Expression of OATP2B1 as determinant of drug effects in the microcompartment of the coronary artery.

Hussner J, Begunk R, Boettcher K, Gliesche DG, Prestin K, Meyer Zu Schwabedissen HE.

Vascul Pharmacol. 2015 Sep;72:25-34. doi: 10.1016/j.vph.2015.06.006. Epub 2015 Jun 16.

PMID:
26091578
17.

Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.

Meyer zu Schwabedissen HE, Albers M, Baumeister SE, Rimmbach C, Nauck M, Wallaschofski H, Siegmund W, Völzke H, Kroemer HK.

Pharmacogenet Genomics. 2015 Jan;25(1):8-18. doi: 10.1097/FPC.0000000000000098.

PMID:
25379722
18.

Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report.

Meyer zu Schwabedissen HE, Siegmund W, Kroemer HK, Rollnik JD.

BMC Res Notes. 2014 Oct 3;7:688. doi: 10.1186/1756-0500-7-688.

19.

Transcriptional regulation of urate transportosome member SLC2A9 by nuclear receptor HNF4α.

Prestin K, Wolf S, Feldtmann R, Hussner J, Geissler I, Rimmbach C, Kroemer HK, Zimmermann U, Meyer zu Schwabedissen HE.

Am J Physiol Renal Physiol. 2014 Nov 1;307(9):F1041-51. doi: 10.1152/ajprenal.00640.2013. Epub 2014 Sep 10.

20.

Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.

Herzog S, Fink MA, Weitmann K, Friedel C, Hadlich S, Langner S, Kindermann K, Holm T, Böhm A, Eskilsson E, Miletic H, Hildner M, Fritsch M, Vogelgesang S, Havemann C, Ritter CA, Meyer zu Schwabedissen HE, Rauch B, Hoffmann W, Kroemer HK, Schroeder H, Bien-Möller S.

Neuro Oncol. 2015 Feb;17(2):223-42. doi: 10.1093/neuonc/nou216. Epub 2014 Aug 25.

21.

Cell-specific expression of uptake transporters--a potential approach for cardiovascular drug delivery devices.

Meyer Zu Schwabedissen HE, Begunk R, Hussner J, Juhnke BO, Gliesche D, Böttcher K, Sternberg K, Schmitz KP, Kroemer HK.

Mol Pharm. 2014 Mar 3;11(3):665-72. doi: 10.1021/mp400245g. Epub 2014 Feb 19.

PMID:
24495124
22.

OATP1B3 is expressed in pancreatic β-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide.

Meyer Zu Schwabedissen HE, Boettcher K, Steiner T, Schwarz UI, Keiser M, Kroemer HK, Siegmund W.

Diabetes. 2014 Feb;63(2):775-84. doi: 10.2337/db13-1005. Epub 2013 Oct 22.

23.

In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvastatin release.

Petersen S, Hussner J, Reske T, Grabow N, Senz V, Begunk R, Arbeiter D, Kroemer HK, Schmitz KP, Meyer zu Schwabedissen HE, Sternberg K.

J Mater Sci Mater Med. 2013 Nov;24(11):2589-600. doi: 10.1007/s10856-013-5001-7. Epub 2013 Jul 12.

PMID:
23846839
24.

Personalized cardiovascular medicine: concepts and methodological considerations.

Völzke H, Schmidt CO, Baumeister SE, Ittermann T, Fung G, Krafczyk-Korth J, Hoffmann W, Schwab M, Meyer zu Schwabedissen HE, Dörr M, Felix SB, Lieb W, Kroemer HK.

Nat Rev Cardiol. 2013 Jun;10(6):308-16. doi: 10.1038/nrcardio.2013.35. Epub 2013 Mar 26. Review.

PMID:
23528962
25.

Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality.

Haring R, Friedrich N, Völzke H, Vasan RS, Felix SB, Dörr M, Meyer zu Schwabedissen HE, Nauck M, Wallaschofski H.

Eur Heart J. 2014 May;35(18):1215-21. doi: 10.1093/eurheartj/ehs233. Epub 2012 Jul 26.

PMID:
22843444
26.

Compartment-specific gene regulation of the CAR inducer efavirenz in vivo.

Meyer zu Schwabedissen HE, Oswald S, Bresser C, Nassif A, Modess C, Desta Z, Ogburn ET, Marinova M, Lütjohann D, Spielhagen C, Nauck M, Kroemer HK, Siegmund W.

Clin Pharmacol Ther. 2012 Jul;92(1):103-11. doi: 10.1038/clpt.2012.34. Epub 2012 May 16. Erratum in: Clin Pharmacol Ther. 2013 Jan;93(1):129. Dosage error in article text.

27.

Inverse association between serum free thyroxine levels and hepatic steatosis: results from the Study of Health in Pomerania.

Ittermann T, Haring R, Wallaschofski H, Baumeister SE, Nauck M, Dörr M, Lerch MM, Meyer zu Schwabedissen HE, Rosskopf D, Völzke H.

Thyroid. 2012 Jun;22(6):568-74. doi: 10.1089/thy.2011.0279. Epub 2012 May 10. Erratum in: Thyroid. 2013 Mar;23(3):381. Lerch, Markus [corrected to Lerch, Markus M].

28.

Meta-analysis of two genome-wide association studies identifies four genetic loci associated with thyroid function.

Rawal R, Teumer A, Völzke H, Wallaschofski H, Ittermann T, Åsvold BO, Bjøro T, Greiser KH, Tiller D, Werdan K, Meyer zu Schwabedissen HE, Doering A, Illig T, Gieger C, Meisinger C, Homuth G.

Hum Mol Genet. 2012 Jul 15;21(14):3275-82. doi: 10.1093/hmg/dds136. Epub 2012 Apr 10.

PMID:
22494929
29.

Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.

Oswald S, Meyer zu Schwabedissen HE, Nassif A, Modess C, Desta Z, Ogburn ET, Mostertz J, Keiser M, Jia J, Hubeny A, Ulrich A, Runge D, Marinova M, Lütjohann D, Kroemer HK, Siegmund W.

Clin Pharmacol Ther. 2012 Mar;91(3):506-13. doi: 10.1038/clpt.2011.255. Epub 2012 Feb 1.

30.

Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.

Koenen A, Kroemer HK, Grube M, Meyer zu Schwabedissen HE.

Expert Rev Clin Pharmacol. 2011 Nov;4(6):729-42. doi: 10.1586/ecp.11.58. Review.

PMID:
22111859
31.

Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis.

Meyer zu Schwabedissen HE, Ware JA, Finkelstein D, Chaudhry AS, Mansell S, Leon-Ponte M, Strom SC, Zaher H, Schwarz UI, Freeman DJ, Schuetz EG, Tirona RG, Kim RB.

Hepatology. 2011 Aug;54(2):644-54. doi: 10.1002/hep.24391. Epub 2011 Jun 26.

32.

In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna.

Cutler MJ, Urquhart BL, Velenosi TJ, Meyer Zu Schwabedissen HE, Dresser GK, Leake BF, Tirona RG, Kim RB, Freeman DJ.

J Clin Pharmacol. 2012 Apr;52(4):530-42. doi: 10.1177/0091270011400414. Epub 2011 Apr 19.

PMID:
21505084
33.

Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels.

Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, Pellikka N, Wallaschofski H, Kettunen J, Henneman P, Baumert J, Strachan DP, Fuchsberger C, Vitart V, Wilson JF, Paré G, Naitza S, Rudock ME, Surakka I, de Geus EJ, Alizadeh BZ, Guralnik J, Shuldiner A, Tanaka T, Zee RY, Schnabel RB, Nambi V, Kavousi M, Ripatti S, Nauck M, Smith NL, Smith AV, Sundvall J, Scheet P, Liu Y, Ruokonen A, Rose LM, Larson MG, Hoogeveen RC, Freimer NB, Teumer A, Tracy RP, Launer LJ, Buring JE, Yamamoto JF, Folsom AR, Sijbrands EJ, Pankow J, Elliott P, Keaney JF, Sun W, Sarin AP, Fontes JD, Badola S, Astor BC, Hofman A, Pouta A, Werdan K, Greiser KH, Kuss O, Meyer zu Schwabedissen HE, Thiery J, Jamshidi Y, Nolte IM, Soranzo N, Spector TD, Völzke H, Parker AN, Aspelund T, Bates D, Young L, Tsui K, Siscovick DS, Guo X, Rotter JI, Uda M, Schlessinger D, Rudan I, Hicks AA, Penninx BW, Thorand B, Gieger C, Coresh J, Willemsen G, Harris TB, Uitterlinden AG, Järvelin MR, Rice K, Radke D, Salomaa V, Willems van Dijk K, Boerwinkle E, Vasan RS, Ferrucci L, Gibson QD, Bandinelli S, Snieder H, Boomsma DI, Xiao X, Campbell H, Hayward C, Pramstaller PP, van Duijn CM, Peltonen L, Psaty BM, Gudnason V, Ridker PM, Homuth G, Koenig W, Ballantyne CM, Witteman JC, Benjamin EJ, Perola M, Chasman DI.

Circulation. 2011 Feb 22;123(7):731-8. doi: 10.1161/CIRCULATIONAHA.110.948570. Epub 2011 Feb 7.

34.

Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.

Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, Mizuguchi K, Ho RH, Kim RB.

Pharmacogenet Genomics. 2011 Mar;21(3):103-14. doi: 10.1097/FPC.0b013e328342f5b1.

35.

In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).

Meyer zu Schwabedissen HE, Kroemer HK.

Handb Exp Pharmacol. 2011;(201):325-71. doi: 10.1007/978-3-642-14541-4_9. Review.

PMID:
21103975
36.

Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1.

Meyer Zu Schwabedissen HE, Böttcher K, Chaudhry A, Kroemer HK, Schuetz EG, Kim RB.

Hepatology. 2010 Nov;52(5):1797-807. doi: 10.1002/hep.23876.

PMID:
20827719
37.

[Pharmacogenomics in routine medical care].

Rosskopf D, Meyer zu Schwabedissen HE, Kroemer HK, Siegmund W.

Dtsch Med Wochenschr. 2010 Jan;135(4):133-44; quiz 145-6. doi: 10.1055/s-0029-1244830. Epub 2010 Jan 25. Review. German.

PMID:
20101557
38.

Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.

Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB.

Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005. doi: 10.1152/ajprenal.00431.2009. Epub 2010 Jan 6.

39.

A piece in the puzzle of personalized medicine.

Kroemer HK, Meyer zu Schwabedissen HE.

Clin Pharmacol Ther. 2010 Jan;87(1):19-20. doi: 10.1038/clpt.2009.219. Review.

PMID:
20019696
40.

Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability.

Ho RH, Leake BF, Kilkenny DM, Meyer Zu Schwabedissen HE, Glaeser H, Kroetz DL, Kim RB.

Pharmacogenet Genomics. 2010 Jan;20(1):45-57. doi: 10.1097/FPC.0b013e3283349eb0.

41.

Human skeletal muscle drug transporters determine local exposure and toxicity of statins.

Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG.

Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25.

PMID:
19940267
42.

Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.

Meyer zu Schwabedissen HE, Kim RB.

Mol Pharm. 2009 Nov-Dec;6(6):1644-61. doi: 10.1021/mp9000298. Review.

PMID:
19558188
43.

Identification, expression, and functional characterization of full-length and splice variants of murine organic anion transporting polypeptide 1b2.

Meyer Zu Schwabedissen HE, Ware JA, Tirona RG, Kim RB.

Mol Pharm. 2009 Nov-Dec;6(6):1790-7. doi: 10.1021/mp900030w.

PMID:
19400585
44.

Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer.

Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB.

Cancer Res. 2008 Nov 15;68(22):9338-47. doi: 10.1158/0008-5472.CAN-08-0265.

45.

Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin.

Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, Palandra J, Stock JL, Kim RB, Ware JA.

Mol Pharmacol. 2008 Aug;74(2):320-9. doi: 10.1124/mol.108.046458. Epub 2008 Apr 15.

46.

Sepsis affects cardiac expression of multidrug resistance protein 5 (MRP5, ABCC5), an ABC-type CGMP export pump.

Meissner K, Kessler W, Meyer zu Schwabedissen HE, Schuster K, Saalfeld K, Grube M, Buck A, Jedlitschky G, Maier S, Traeger T, Mostertz J, Homuth G, Heidecke CD, Lehmann C, Kroemer HK.

Shock. 2007 Nov;28(5):564-9.

PMID:
17589384
47.

Direct mass spectrometric identification of ABCB1 (P-glycoprotein/MDR1) from the apical membrane fraction of human placenta using fourier transform ion cyclotron mass spectrometry.

Meyer zu Schwabedissen HE, Dreisbach A, Hammer E, Fusch C, Hecker M, Völker U, Kroemer HK.

Pharmacogenet Genomics. 2006 Jun;16(6):385-9.

PMID:
16708047
48.

Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5).

Grube M, Meyer zu Schwabedissen HE, Präger D, Haney J, Möritz KU, Meissner K, Rosskopf D, Eckel L, Böhm M, Jedlitschky G, Kroemer HK.

Circulation. 2006 Feb 28;113(8):1114-22. Epub 2006 Feb 20.

PMID:
16490820
49.

Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).

Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter CA, Völker U, Kroemer HK.

Drug Metab Dispos. 2006 Apr;34(4):524-33. Epub 2006 Jan 13.

50.

Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation.

Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK.

Drug Metab Dispos. 2005 Jul;33(7):896-904. Epub 2005 Apr 8.

Supplemental Content

Loading ...
Support Center